

Diferansiye Tiroid Kanserlerinde Kemoterapi ve Hedef Tedaviler

- Uzm. Dr. Mutlu HIZAL
- Doç. Dr. Mehmet Ali Nahit ŞENDUR

Özet

Tiroid kanserleri 2018 yılı verilerine göre tüm dünyada görülen yeni kanser vakalarının %3,1'ine ve kanser ilişkili mortalitenin %0,4'üne neden olurlar. Literatürde metastaz geliştiren hastaların oranı %7-23 olarak bildirilmiştir ve bu hastaların 2/3'ü radyoaktif iyot (RAİ) tedavisine direnç geliştirmektedir. RAİ refrakter hastalar için ise metastaz saptanan andan itibaren beklenen 10 yıllık sağkalım %10'a inmektedir. RAİ refrakter diferansiye tiroid kanserlerinin patogeneziyle ilişkin bilgilerimizde ve hastalığa karşı geliştirilen tedavilerin etkinliğinde son on yılda ciddi gelişmeler mevcuttur. Sitotoksik kemoterapilerle elde edilemeyen yanıt oranları ve hastalık kontrol sürelerine hedeflenmiş tedavilerle ulaşılmıştır. Sorafenib ve Lenvatinib başta olmak üzere anti-VEGF tedaviler, V600E mutasyonu olan hastalarda BRAF inhibitörleri, kanser alt tipinden bağımsız kullanılan TRK inhibitörleri gibi birçok hedeflenmiş tedavi ajanı etkinlik göstermiştir. Bir diğer başlık henüz tiroid kanseri tedavisinde aktif rol almayan ancak günümüz itibarıyla kanser tarihinde ciddi kırılmalara yol açan immünoterapidir. Kontrol noktası inhibitörleri olan İpilimumab, Nivolumab, Pembrolizumab, Atezolizumab, Durvalumab ve Avelumab birçok kanser tipinde kullanılmaktadır. Tiroid kanserlerinde de bu ajanların monoterapi veya kombinasyon halinde test edildiği birçok çalışma devam etmektedir.

Tablo 2 Diferansiye Tiroid Kanserlerinde Devam Eden Bazı Faz 2 ve 3 Çalışmalar

Çalışmanın Adı	Kodu	Fazı	İlaç	Bitiş Tarihi
Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer	NCT03630120	2	Lenvatinib, Sorafenib, Cabozantinib, Vandetanib	Aralık 2023
Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer	NCT02393690	2	Selumetinib+ RAİ	Ağustos 2020
Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer	NCT02152995	2	Trametinib	?
Nivolumab Plus Ipilimumab in Thyroid Cancer	NCT03246958	2	Nivolumab+ Ipilimumab	Mart 2025
Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial	NCT03753919	2	Durvalumab+ Tremelimumab	Temmuz 2021

Kaynaklar

- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin.* 2018;68(6):394-424.
- TC Sağlık Bakanlığı, Halk Sağlığı Genel Müdürlüğü, Kanser Daire Başkanlığı. Türkiye Kanser İstatistikleri. Ankara, 2017.
- Noone AM, Howlader N, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2015, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2015/, based on November 2017 SEER data submission, posted to the SEER web site, April 2018.
- Amin, M.B., Edge, S., Greene, F. AJCC Cancer Staging Manual, 8th Edition. Springer International Publishing, 2017.
- National Comprehensive Cancer Network, NCCN Clinical Practice Guidelines in Oncology, Thyroid Carcinoma, Version 1.2019, 2019.
- Shoup M, Stojadinovic A, Nissan A, Ghossein RA, Freedman S, Brennan MF, et al. Prognostic indicators of outcomes in patients with distant metastases from differentiated thyroid carcinoma. *J Am Coll Surg.* 2003;197(2):191-7.
- Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travaglini JP, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. *J Clin Endocrinol Metab.* 2006;91(8):2892-9.
- Schlumberger M, Brose M, Elisei R, Leboulleux S, Luster M, Pitoia F, et al. Definition and management of radioactive iodine-refractory differentiated thyroid cancer. *Lancet Diabetes Endocrinol.* 2014;2(5):356-8.
- Sherman SI. Cytotoxic chemotherapy for differentiated thyroid carcinoma. *Clin Oncol (R Coll Radiol).* 2010;22(6):464-8.
- Harada T, Nishikawa Y, Suzuki T, Ito K, Baba S. Bleomycin treatment for cancer of the thyroid. *Am J Surg.* 1971;122(1):53-7.
- Droz JP, Schlumberger M, Rougier P, Ghosn M, Gardet P, Parmentier C. Chemotherapy in metastatic nonanaplastic thyroid cancer: experience at the Institut Gustave-Roussy. *Tumori.* 1990;76(5):480-3.
- Leaf AN, Wolf BC, Kirkwood JM, Haselow RE. Phase II study of etoposide (VP-16) in patients with thyroid cancer with no prior chemotherapy: an Eastern Cooperative Oncology Group Study (E1385). *Med Oncol.* 2000;17(1):47-51.
- Gottlieb JA, Hill CS, Jr., Ibanez ML, Clark RL. Chemotherapy of thyroid cancer. An evaluation of experience with 37 patients. *Cancer.* 1972;30(3):848-53.
- Shimaoka K, Schoenfeld DA, DeWys WD, Creech RH, DeConti R. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. *Cancer.* 1985;56(9):2155-60.
- Matuszczyk A, Petersenn S, Voigt W, Kegel T, Dralle H, Schmoll HJ, et al. Chemotherapy with paclitaxel and gemcitabine in progressive medullary and thyroid carcinoma of the follicular epithelium. *Horm Metab Res.* 2010;42(1):61-4.
- Hanauske AR, Dumez H, Piccart M, Yilmaz E, Graefe T, Gil T, et al. Pemetrexed combined with paclitaxel: a dose-finding study evaluating three schedules in solid tumors. *Invest New Drugs.* 2009;27(4):356-65.
- Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumori-

- genesis. *Cell*. 1996;86(3):353-64.
18. Verheul HM, Voest EE, Schlingemann RO. Are tumours angiogenesis-dependent? *J Pathol*. 2004;202(1):5-13.
 19. Ivy SP, Wick JY, Kaufman BM. An overview of small-molecule inhibitors of VEGFR signaling. *Nat Rev Clin Oncol*. 2009;6(10):569-79.
 20. Roy H, Bhardwaj S, Yla-Herttuala S. Biology of vascular endothelial growth factors. *FEBS Lett*. 2006;580(12):2879-87.
 21. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. *Nat Med*. 2003;9(6):669-76.
 22. Erdem H, Gundogdu C, Sipal S. Correlation of E-cadherin, VEGF, COX-2 expression to prognostic parameters in papillary thyroid carcinoma. *Exp Mol Pathol*. 2011;90(3):312-7.
 23. Klein M, Vignaud JM, Hennequin V, Toussaint B, Bresler L, Plenat F, et al. Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma. *J Clin Endocrinol Metab*. 2001;86(2):656-8.
 24. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. *Cancer Res*. 2004;64(19):7099-109.
 25. Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, et al. Phase II trial of sorafenib in advanced thyroid cancer. *J Clin Oncol*. 2008;26(29):4714-9.
 26. Kloos RT, Ringel MD, Knopp MV, Hall NC, King M, Stevens R, et al. Phase II trial of sorafenib in metastatic thyroid cancer. *J Clin Oncol*. 2009;27(10):1675-84.
 27. Massicotte MH, Brassard M, Claude-Desroches M, Borget I, Bonichon F, Giraudet AL, et al. Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network. *Eur J Endocrinol*. 2014;170(4):575-82.
 28. Hoftijzer H, Heemstra KA, Morreau H, Stokkel MP, Corssmit EP, Gelderblom H, et al. Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. *Eur J Endocrinol*. 2009;161(6):923-31.
 29. Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. *Lancet*. 2014;384(9940):319-28.
 30. Boss DS, Glen H, Beijnen JH, Keesen M, Morrison R, Tait B, et al. A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours. *Br J Cancer*. 2012;106(10):1598-604.
 31. Cabanillas ME, Schlumberger M, Jarzab B, Martins RG, Pacini F, Robinson B, et al. A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment. *Cancer*. 2015;121(16):2749-56.
 32. Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. *N Engl J Med*. 2015;372(7):621-30.
 33. Tahara M, Schlumberger M, Elisei R, Habra MA, Kiyota N, Paschke R, et al. Exploratory analysis of biomarkers associated with clinical outcomes from the study of lenvatinib in differentiated cancer of the thyroid. *Eur J Cancer*. 2017;75:213-21.
 34. Carr LL, Mankoff DA, Goulart BH, Eaton KD, Capell PT, Kell EM, et al. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. *Clin Cancer Res*. 2010;16(21):5260-8.
 35. Ravaud A, de la Fouchardiere C, Caron P, Doussau A, Do Cao C, Asselineau J, et al. A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU study. *Eur J Cancer*. 2017;76:110-7.
 36. Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. *J Clin Oncol*. 2008;26(29):4708-13.
 37. Cohen EE, Tortorici M, Kim S, Ingrosso A, Pithavala YK, Bycott P. A Phase II trial of axitinib in patients with various histologic subtypes of advanced thyroid cancer: long-term outcomes and pharmacokinetic/pharmacodynamic analyses. *Cancer Chemother Pharmacol*. 2014;74(6):1261-70.
 38. Locati LD, Licitra L, Agate L, Ou SH, Boucher A, Jarzab B, et al. Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments. *Cancer*. 2014;120(17):2694-703.
 39. Bible KC, Suman VJ, Molina JR, Smallridge RC, Maples WJ, Meneff ME, et al. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. *Lancet Oncol*. 2010;11(10):962-72.
 40. Leboulleux S, Bastholt L, Krause T, de la Fouchardiere C, Tennvall J, Awada A, et al. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. *Lancet Oncol*. 2012;13(9):897-905.
 41. Cabanillas ME, Brose MS, Holland J, Ferguson KC, Sherman SI. A phase I study of cabozantinib (XL184) in patients with differentiated thyroid cancer. *Thyroid*. 2014;24(10):1508-14.
 42. Cabanillas ME, Souza JAd, Geysler S, Wirth LJ, Meneff ME, Liu SV, et al. Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor-Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial. *Journal of Clinical Oncology*. 2017;35(29):3315-21.
 43. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activa-

- ted protein kinase cascade for the treatment of cancer. *Oncogene*. 2007;26(22):3291-310.
44. Xing M. BRAF mutation in thyroid cancer. *Endocr Relat Cancer*. 2005;12(2):245-62.
 45. Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. *J Clin Endocrinol Metab*. 2005;90(12):6373-9.
 46. Xing M, Alzahrani AS, Carson KA, Viola D, Elisei R, Bendlova B, et al. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. *JAMA*. 2013;309(14):1493-501.
 47. Kim KB, Cabanillas ME, Lazar AJ, Williams MD, Sanders DL, Ilagan JL, et al. Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation. *Thyroid*. 2013;23(10):1277-83.
 48. Brose MS, Cabanillas ME, Cohen EE, Wirth LJ, Riehl T, Yue H, et al. Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial. *Lancet Oncol*. 2016;17(9):1272-82.
 49. Falchook GS, Millward M, Hong D, Naing A, Piha-Paul S, Wagüespack SG, et al. BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer. *Thyroid*. 2015;25(1):71-7.
 50. Rothenberg SM, McFadden DG, Palmer EL, Daniels GH, Wirth LJ. Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib. *Clin Cancer Res*. 2015;21(5):1028-35.
 51. Hall MN. mTOR-what does it do? *Transplant Proc*. 2008;40(10 Suppl):S5-8.
 52. Liu D, Hou P, Liu Z, Wu G, Xing M. Genetic alterations in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin. *Cancer Res*. 2009;69(18):7311-9.
 53. Lim SM, Chang H, Yoon MJ, Hong YK, Kim H, Chung WY, et al. A multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes. *Ann Oncol*. 2013;24(12):3089-94.
 54. Schneider TC, de Wit D, Links TP, van Erp NP, van der Hoeven JJ, Gelderblom H, et al. Everolimus in Patients With Advanced Follicular-Derived Thyroid Cancer: Results of a Phase II Clinical Trial. *J Clin Endocrinol Metab*. 2017;102(2):698-707.
 55. Chao MV. Neurotrophins and their receptors: A convergence point for many signalling pathways. *Nature Reviews Neuroscience*. 2003;4(4):299-309.
 56. Russell JP, Powell DJ, Cunnane M, Greco A, Portella G, Santoro M, et al. The TRK-T1 fusion protein induces neoplastic transformation of thyroid epithelium. *Oncogene*. 2000;19(50):5729-35.
 57. Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, et al. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. *N Engl J Med*. 2018;378(8):731-9.